Efficacy of montelukast and desloratadine combination in allergic rhinitis

Abstract

Allergic rhinitis represents a global health problem affecting 10 to 25% of the population worldwide. The complications i.e. sinusitis, nasal polyps, middle ear and lower respiratory tract infections increase the importance of allergic rhinitis. Besides treatment costs, due to wage loss and decrease in productive capacity it has a huge negative impact on community. It may also seriously affect quality of life. Despite recent developments in its treatment modalities, several studies have indicated that the prevalence of allergic rhinitis is increasing. New knowledge on the mechanisms underlying allergic inflammation of the airways has resulted in better therapeutic strategies for allergic rhinitis. Montelukast and desloratadine has powerful effects on allergic rhinitis. Since studies demonstrate that both products have better pharmacodynamic and pharmacokinetic profiles, and having side effects similar to placebo, they are better options for this sub-group. The concomitant use of both drugs is believed to provide a better control on the symptoms of allergic rhinitis. The combination therapy possibly provides a more potential reduction in early and late allergic and inflammatory response to histamine and histamine like mediators during allergen inhalation. Including a fixed dose combination of montolukast-desloratadine to the treatment strategy seems to be a more rational and cost effective approach in these groups of patients.

Keywords

• Montelukast, desloratadine, allergic rhinitis

Alerjik rinitte montelukast ve desloratadin kombinasyonunun etkinliği

Öz

Alerjik rinit dünya nüfusunun %10-25'ini etkileyen önemli bir sağlık sorunudur. Sinüzit, nazal polipozis, orta kulak ve alt solunum yolu enfeksiyonlarına da yol açabilmesi alerjik rinitin önemini artırmaktadır. Tedavi maliyetlerinin yanı sıra hastalığın yol açtığı işgücü kaybı ve üretkenlikteki azalma nedeniyle, bu hastalığın toplumsal maliyeti çok büyük ölçüdedir. Yaşam kalitesine etkisi ise beklenenin çok üzerindedir. Son yıllarda alerjik rinit tedavisinde yeni gelişmeler sağlanmasına rağmen, araştırmalar hastalığın sıklığında artış olduğunu göstermektedir. Hava yolu enflamasyonunun altında yatan mekanizmalara ilişkin son yıllarda ortaya çıkan gelişmeler, alerjik rinit tedavisinde yeni stratejiler geliştirilmesini sağlamıştır. Montekulast ve desloratadin alerjik rinit tedavisinde kullanılan güçlü etken maddelerdir. Farmakodinamik ve farmakokinetik profillerinin çok iyi olmaları ve yan etkilerinin plaseboya benzer olması gibi nedenlerle aynı sınıftaki etken maddelere göre üstünlükleri bildirilmektedir. Semptom kontrolünün yeterince sağlanamadığı durumlarda her iki ilacın birlikte kullanılmasının alerjik rinitin kontrolünü daha iyi sağlayacağı düşünülmektedir. Kombinasyon tedavisi ile alerjen inhalasyonu sırasında erken ve geç dönemlerde ortaya çıkan histamin ve histamin dışındaki mediatörlerin de, alerjik ve enflamatuvar yanıtları daha güçlü şekilde bastırmak mümkün olabilmektedir. Bu tip hastalarda tedaviye montelukast-desloratadin fiks kombine preparatının günde tek doz eklenmesi rasyonel ve maliyeti azaltan bir yaklaşım tarzı gibi görünmektedir.

Anahtar Kelimeler

• Montelukast, desloratadin, alerjik rinit

Kaynakça

1. Woods L, Craig TJ. The importance of rhinitis on sleep, day- time somnolence, productivity and fatigue. Curr Opin Pulm Med 2006;12:390-6.
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy 2008;63(Suppl 86):8- 160.
3. Günen H. Astım ve alerjik rinit tedavisinde sinerjistik kombi- nasyon. Göğüs Hastalıkları Serisi 2011;2:1-16.
4. Law AW, Reed SD, Sundy J, et al. Direct costs of allergic rhini- tis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003;111: 296-300.
5. Cingi C, Topuz B, Songu M, et al. Prevalence of allergic rhini- tis among the adult population in Turkey. Acta Otolaryngol 2010;130:600-6.
6. Cingi C. Alerjik rinit, önemi, tanısı, tedavisi. KBB'de Trent 2009; 3:4-11.
7. Bostan Ö. Hafif persistan astımlı çocuklarda lökotrien reseptör antagonisti ile inhale kortikosteroid etkinliğinin karşılaştırılması. Uzmanlık tezi, İstanbul, 2005.
8. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant mon- telukast and loratadine as treatment for seasonal allergic rhinitis: a randomized placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917-22.

9. Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of mon- telukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter randomized double blind placebo- controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592-60.
10. Philip G, Nayak A, Berger W, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal aller- gic rhinitis. Curr Med Res Opin 2004;10:1549-58.
11. Van Adelsberg J, Philip G, LaForce CF, et al. Randomized con- trolled trial evaluating clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214-22.
12. Van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003;58:1268-76.
13. Kurowski M, Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004;59:280-8.
14. Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glu- cocorticoid, anti-leukotriene and a combination of anti- leukotriene and anti-histamine in the treatment of seasonal aller- gic rhinitis. J Allergy Clin Immunol 2004;109:949-55.
15. Perry TT, Coren J, Philip G, et al. Protective effect of mon- telukast on lower and upper respiratory tract responses to short- term cat allergen exposure. Ann Allergy Astma Immunol 2004; 93:431-8.
16. Patel P, Philip G, Yang W, et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perrenial allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:551-7.
17. Ciebiada M, Ciebiada MG, Kmiecik T, et al. Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine. J Investig Allergol Immunol 2008;18:343-9.
18. Mastalerz L, Kumik J. Antileokotriene drugs in the treatment of asthma. Pol Arch Med Wewn 2010;120:103-8.
19. Diamant Z, Mantzouranis E, Bjermer L. Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol 2009;5:639-58.
20. Warner JO, Naspitz CK, Maria CR. Management of chronic asthma in children between 5 and 18 years of age. In: Naspitz CK, Szefler SJ, Tinkelman DG, Warner JO, editors. Textbook of Pediatric Asthma: An International Perspective. London: Martin Dunitz, 2001. p. 149-88.
21. Liu MC, Dube LM, Lancaster J, et al. Zileuton Study Group: Acute and chronic effects of a 5-lipoxygenase inhibitor in asth- ma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996;98:859-71.
22. Scow DT, Luttermoser GK, Dickerson KS. Leukotriene inhibitors in the treatment of allergy and asthma. Am Fam Physician 2007;75:65-70.
23. Markham A, Faulds D. Montelukast. Drugs 1998;56:251-6.
24. Harrold LR, Patterson K, Andrade SE, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmaco-epidemiol Drug Saf 2007;16:620-6.
25. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351:2203-17.
26. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001;56:1077-80
27. See S. Desloratadine for allergic rhinitis. Am Fam Physcian 2003;68:2015-6.
28. Price DB, Swern A, Tozzi CA, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006;61:737-42.
29. Cingi C, Songu M. Alerjik rinit tedavisinde kanıta dayalı yakla- şım. İç: Kulak Burun Boğazda Kanıta Dayalı Tanı ve Tedavi. Ed: Cemal Cingi. Sebad Yayınları, 2011, Eskişehir.
30. Cingi C, Ozlugedik S. Effects of montelukast on quality of life in patients with persistent allergic rhinitis. Otolaryngol Head Neck Surg 2010;142:654-58.
31. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002;32:1020-8.
32. Jiang RS. Efficacy of a leukotriene receptor antagonist in the treatment of perennial allergic rhinitis. J Otolaryngol 2006;35: 117-21.
33. Howarth PH, Salagean M, Dokic D. Allergic rhinitis: not pure- ly a histamine-related disease. Allergy 2000;55:7-16.
34. Bousquet J, Bachert C, Canonica GW, et al. Efficacy of deslo- ratadine in intermittent allergic rhinitis: a GA(2)LEN study. Allergy 2009;64:1516-23.
35. Bachert C, van Cauwenberge P. Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Clin Ther 2007;29:1795-802.
36. Meltzer EO, Jalowayski AA, Vogt K, et al. Effect of deslorata- dine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis. Results of a single-center, placebo- controlled trial. Ann Allergy Asthma Immunol 2006;96:363-8.
37. Pradalier A, Neukirch C, Dreyfus I, et al. Desloratadine improves quality of life and symtom severity in patients with allergic rhinitis. Allergy 2007;62:1331-4.
38. Bousquet J, Bachert C, Canonica GW. Efficacy of desloratidine in persistant allergic rhinitis - a GA2 LEN study. Int Arch Allergy Immunol 2010;153:395-402.
39. Berger WE, Schenkel EJ, Mansfield LE for the Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asth- ma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma 2002;89:485-91.
40. Sadowska-Woda I, Bieszczad-Bedrejczuk E, Rachel M. Influence of desloratadine on selected oxidative stress markers in patients between 3 and 10 years of age with allergic perennial rhinitis. Eur J Pharmacol 2010;640:197-201.
41. Tonnel AB, Holmberg K, Sauvage N, et al. Desloratadine improves health-related quality of life in persistent allergic rhini- tis. Presented at 23rd Congress of European Academy of Allergy and Clinical Immunology: June 12-16, 2004, Amsterdam, The Netherlands.
42. Holmberg K. Effectiveness of desloratadine in relieving morning symptoms of perennial allergic rhinitis (PAR). Presented at Annual Scientific Meeting of American College of Allergy, Asthma and Immunology: November 4-9, 2005, Anaheim, California, USA.
43. Holmberg K, Tonnel AB, Dreyfus I, et al. Desloratadine relieves nasal congestion and improves quality-of-life in persistent aller- gic rhinitis. Allergy 2009;64:1663-70.
44. Sullivan PW, Navaratnam P, Lorber R, et al. The cost-effective- ness of treatment with desloratadine in patients with persistent allergic rhinitis. Curr Med Res Opin 2010;26:1389-97.
45. Borade PS, Ballary CC, Currie GP, et al. Modern H1- Antihistamines in asthma. Drugs 2006;3:253-9 .
46. Cingi C, Gunhan K, Gage-White L, et al. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhini- tis. Laryngoscope 2010;120:1718-23.
47. Bu açık erişim makalenin, ticari kullanım amacı ve içerik değişikliği dışında kalan çoğaltma, dağıtma vb. tüm kullanım hakları, bilinen standartlarda kay
48. nak olarak gösterilmesi koşuluyla Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) Lisansı aracılığıyla
49. (http://creativecommons.org/licenses/by-nc-nd/3.0/) bedelsiz kullanıma sunulmuştur.
50. Makalenin atıf künyesi: Cingi C, Oğhan F, Ünlü H, Tekat A, Okuyucu Ş. Alerjik rinitte montelukast ve desloratadin kombinasyonunun etkinliği.
51. J Med Updates 2011;1(1):3-16.